Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avastin Decision Leaves Lingering Uncertainty As To Threshold Level Of Progression-Free Survival Benefit

Executive Summary

In her memo revoking Avastin’s metastatic breast cancer claim, FDA Commissioner Hamburg declines to adopt a “bright-line” cutoff of median PFS improvement that would be necessary to establish efficacy, despite industry’s desire for more certainty about the threshold for approval.

You may also be interested in...



The Magnitude Matters: GSK Approvals Show How To Use PFS After Other Drugs Show Survival

Submitting an NDA based on progression-free survival when other drugs for the indication have been approved on the basis of overall survival benefits is a risky proposition, but GlaxoSmithKline was confident the magnitude of Mekinist and Tafinlar’s PFS effect in metastatic melanoma would make the findings clinically relevant.

Cancer Trials Should Show Minimum 20% Overall Survival Benefit, ASCO Suggests

American Society of Clinical Oncology draft recommendations provide benchmarks for Phase III oncology drug trials, including a minimum 20% improvement in overall survival, with a higher bar for certain diseases.

Genentech Thinks Pertuzumab Will Escape Avastin Problem, Despite Similarities

Genentech is confident about a Dec. 6 BLA filing for the monoclonal antibody pertuzumab in HER2 positive metastatic breast cancer with FDA, even though the application is based on a PFS benefit in a single trial.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS053977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel